Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 371
Filtrar
1.
J Insect Sci ; 14: 110, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25205015

RESUMO

Non-native plant species can provide native generalist insects, including pests, with novel food and habitats. It is hypothesized that local and landscape-level abundances of non-native plants can affect the population size of generalist insects, although generalists are assumed to be less sensitive to habitat connectivity than specialists. In a heterogeneous landscape in Japan, the relationship between the density of a native pest of rice (Stenotus rubrovittatus (Matsumura) (Heteroptera: Miridae)) and the abundance of Italian ryegrass (Lolium multiflorum Lam. (Poales: Poaceae)), a non-native meadow grass known to facilitate S. rubrovittatus, was analyzed. Statistical analyses of data on bug density, vegetation, and the spatial distribution of fallow fields and meadows dominated by Italian ryegrass, obtained by field surveys, demonstrated that local and landscape-level abundances of Italian ryegrass (the unmowed meadow areas within a few hundred meters of a sampling plot) positively affected bug density before its immigration into rice fields. Our findings suggest that a generalist herbivorous insect that prefers non-native plants responds to spatial availability and connectivity of plant species patches at the metapopulation level. Fragmentation by selective mowing that decreases the total area of source populations and increases the isolation among them would be an effective and environmentally-friendly pest management method.


Assuntos
Heterópteros/fisiologia , Interações Hospedeiro-Parasita , Lolium/parasitologia , Oryza/parasitologia , Animais , Ecossistema , Herbivoria , Japão , Dinâmica Populacional
2.
J Thromb Haemost ; 12(2): 206-213, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24735117

RESUMO

BACKGROUND: We previously reported that a humanized anti-factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII even in the presence of FVIII inhibitors, and has preventive hemostatic activity against bleeding in an animal model of acquired hemophilia A. After further molecular engineering of hBS23, we recently identified an improved humanized bispecific antibody, ACE910, for clinical investigation. OBJECTIVES: To elucidate the in vivo hemostatic potency of ACE910 by examining its effect against ongoing bleeds, and to determine its pharmacokinetic parameters for discussion of its potency for prophylactic use. METHODS: A non-human primate model of acquired hemophilia A was established by injecting anti-primate FVIII neutralizing antibody. When bleeds emerged following an artificial bleed-inducing procedure, either ACE910 or recombinant porcine FVIII (rpoFVIII) was intravenously administered. rpoFVIII was additionally administered twice daily on the following 2 days. Bleeding symptoms were monitored for 3 days. A pharmacokinetic study and multiple-dosing simulations of ACE910 were also performed. RESULTS: A single bolus of 1 or 3 mg kg-1 ACE910 showed hemostatic activity comparable to that of 10 U kg-1 (twice daily) rpoFVIII against ongoing bleeds. The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%). The simulation results based on pharmacokinetic parameters indicated that the above hemostatic level could be maintained with once-weekly subcutaneous administration of ACE910, suggesting the possibility of more effective prophylaxis. CONCLUSIONS: ACE910 may offer an alternative on-demand treatment option for patients with hemophilia A, as well as user-friendly and aggressive routine supplementation.

3.
J Thromb Haemost ; 12(2): 206-13, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24738137

RESUMO

BACKGROUND: We previously reported that a humanized anti-factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII even in the presence of FVIII inhibitors, and has preventive hemostatic activity against bleeding in an animal model of acquired hemophilia A. After further molecular engineering of hBS23, we recently identified an improved humanized bispecific antibody, ACE910, for clinical investigation. OBJECTIVES: To elucidate the in vivo hemostatic potency of ACE910 by examining its effect against ongoing bleeds, and to determine its pharmacokinetic parameters for discussion of its potency for prophylactic use. METHODS: A nonhuman primate model of acquired hemophilia A was established by injecting anti-primate FVIII neutralizing antibody. When bleeds emerged following an artificial bleed-inducing procedure, either ACE910 or recombinant porcine FVIII (rpoFVIII) was intravenously administered. rpoFVIII was additionally administered twice daily on the following 2 days. Bleeding symptoms were monitored for 3 days. A pharmacokinetic study and multiple-dosing simulations of ACE910 were also performed. RESULTS: A single bolus of 1 or 3 mg kg⁻¹ ACE910 showed hemostatic activity comparable to that of 10 U kg⁻¹ (twice daily) rpoFVIII against ongoing bleeds. The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%). The simulation results based on pharmacokinetic parameters indicated that the above hemostatic level could be maintained with once-weekly subcutaneous administration of ACE910, suggesting the possibility of more effective prophylaxis. CONCLUSIONS: ACE910 may offer an alternative on-demand treatment option for patients with hemophilia A, as well as user-friendly and aggressive routine supplementation.


Assuntos
Anticorpos/imunologia , Fator IXa/imunologia , Fator X/imunologia , Hemofilia A/terapia , Hemostasia/imunologia , Animais , Células CHO , Cricetinae , Cricetulus , Reações Cruzadas , Modelos Animais de Doenças , Células HEK293 , Humanos , Macaca fascicularis , Masculino
5.
Haemophilia ; 17(5): 771-6, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21682824

RESUMO

Studies conducted in European and North American countries have demonstrated that various factors including races affect the frequency of inhibitor formation in haemophilia patients. The present study was undertaken to analyse factors affecting the incidence of inhibitor formation in Japanese haemophilia A and B patients. Analytical data were retrospectively collected from haemophilia A and B patients born after 1988, the year when monoclonal antibody-purified factor VIII products were first marketed in Japan. Various data were collected from 184 patients (153 cases of haemophilia A; 31 cases of haemophilia B). The sample size of haemophilia B cases was too small to reveal any significant differences between the inhibitor formation group and the inhibitor-free group in any of background variables. For patients with haemophilia A, on the other hand, univariate analysis identified the severity of haemophilia and a positive family history of inhibitor development as risk factors for the formation of inhibitors. In analyses of the clotting factor products used, the incidence of inhibitor formation did not differ significantly between the group treated with plasma-derived products (29.7%) and the group treated with recombinant products (25.0%). When background variables were compared, age was higher in the group treated with plasma-derived products but none of the other background variables differed between the two groups. These results suggest that in Japanese haemophilia patients, the type of clotting factor preparations used for therapy has not influenced the incidence of inhibitor formation.


Assuntos
Coagulantes/imunologia , Fator IX/imunologia , Fator VIII/imunologia , Hemofilia A/imunologia , Hemofilia B/imunologia , Isoanticorpos/imunologia , Adolescente , Adulto , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/uso terapêutico , Criança , Pré-Escolar , Coagulantes/uso terapêutico , Fator IX/uso terapêutico , Fator VIII/uso terapêutico , Feminino , Hemofilia A/tratamento farmacológico , Hemofilia B/tratamento farmacológico , Humanos , Japão , Masculino , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Fatores de Risco , Adulto Jovem
6.
Allergy ; 66(3): 428-33, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21083568

RESUMO

BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CU) has recently been conceived to be associated with thrombin generation through the extrinsic coagulation pathway. However, little is known about the components of the intrinsic coagulation pathway potentially involved. METHODS: To investigate the whole process of coagulation, both classical coagulation assays and a global coagulation test, the intrinsic coagulation pathway-dependent activated partial thromboplastin time (APTT) clot waveform analysis, were performed using plasma of 36 patients with CU who had various severities. RESULTS: Classical coagulation assays revealed that levels of fibrinogen, D-dimer, and fibrin and fibrinogen degradation products (FDP), and positive rates of soluble fibrin monomer complex (SFMC) were significantly elevated in patients with CU, whereas the elevation of prothrombin fragment 1 + 2 was not statistically significant. On the other hand, all parameters of a global coagulation test, APTT clot waveform analysis, evidently showed a hypercoagulable pattern and were significantly correlated to disease severity of CU. CONCLUSIONS: CU is characterized by elevated blood coagulation potential with involvement of the intrinsic coagulation factors, which may contribute in vivo to the generation of fibrin even by small amounts of thrombin.


Assuntos
Coagulação Sanguínea , Urticária/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Testes de Coagulação Sanguínea , Estudos de Casos e Controles , Criança , Doença Crônica , Humanos , Pessoa de Meia-Idade , Adulto Jovem
7.
Int J Lab Hematol ; 32(6 Pt 2): 598-605, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20201994

RESUMO

The mean myeloperoxidase index (MPXI) is calculated during the routine complete blood count performed using the autoanalyzer ADVIA120/2120. The pattern of changes in the neutrophil myeloperoxidase levels in patients with specific infectious diseases was analyzed by assessing the MPXI levels. In patients with bacterial sepsis, identified by positive blood-culture tests, with (n = 29) and without (n = 51) systemic inflammatory response syndrome, the mean MPXI significantly reduced to -3.18 and -2.06, respectively. In contrast, among patients with nontuberculous nonseptic bacterial infections (n = 40), the mean MPXI significantly elevated to 5.51, while tuberculosis patients (n = 37) and patients with viral infection (n = 60) showed an unchanged MPXI (mean values, -0.46 and -1.06, respectively). Among the parameters of inflammation, only the C-reactive protein values showed a weak correlation with the MPXI levels. [Conclusion] These results indicate that MPXI is correlated with some specific infectious states, i.e. MPXI is low in bacterial sepsis and high in nontuberculous nonseptic bacterial infections. MPXI appears to be an independent and useful biomarker for the diagnosis and follow-up of infectious diseases, especially when the MPXI values are obtained at regular intervals during the disease courses of the patients.


Assuntos
Infecções Bacterianas/enzimologia , Neutrófilos/enzimologia , Peroxidase/sangue , Adolescente , Adulto , Infecções Bacterianas/sangue , Biomarcadores/sangue , Proteína C-Reativa/análise , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Inflamação/enzimologia , Masculino , Pessoa de Meia-Idade , Sepse/sangue , Sepse/enzimologia , Tuberculose/sangue , Tuberculose/enzimologia
10.
J Thromb Haemost ; 6(8): 1352-9, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18485084

RESUMO

BACKGROUND: Hemophilia A is an X-chromosome-linked recessive bleeding disorder resulting from an F8 gene abnormality. Although various gene therapies have been attempted with the aim of eliminating the need for factor VIII replacement therapy, obstacles to their clinical application remain. OBJECTIVES: We evaluated whether embryonic stem (ES) cells with a tetracycline-inducible system could secrete human FVIII. METHODS AND RESULTS: We found that embryoid bodies (EBs) developed under conditions promoting liver differentiation efficiently secreted human FVIII after doxycycline induction. Moreover, use of a B-domain variant F8 cDNA (226aa/N6) dramatically enhanced FVIII secretion. Sorting based on green fluorescent protein (GFP)-brachyury (Bry) and c-kit revealed that GFP-Bry(+)/c-kit(+) cells during EB differentiation with serum contain an endoderm progenitor population. When GFP-Bry(+)/c-kit(+) cells were cultured under the liver cell-promoting conditions, these cells secreted FVIII more efficiently than other populations tested. CONCLUSION: Our findings suggest the potential for future development of an effective ES cell-based approach to treating hemophilia A.


Assuntos
Células-Tronco Embrionárias/metabolismo , Fator VIII/biossíntese , Hemofilia A/tratamento farmacológico , Técnicas de Cultura de Células/métodos , Diferenciação Celular , Doxiciclina/farmacologia , Células-Tronco Embrionárias/citologia , Fator VIII/genética , Expressão Gênica/efeitos dos fármacos , Variação Genética , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Humanos , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética
12.
Artigo em Inglês | MEDLINE | ID: mdl-18361106

RESUMO

A 10-day-old male neonate was admitted with bilious vomiting and gross hematochezia. Peripheral eosinophilia, delayed positive skin prick test to artificial milk, and elevated eosinophil cationic protein levels suggested cow's milk allergy. Fluid infusion with prohibition of oral intake improved the digestive symptoms. Breast-feeding was resumed on hospital day 3 and only casein hydrolysate formula was fed from day 7 onward. Nevertheless, eosinophilia and elevated transaminase levels developed on day 14. Liver dysfunction associated with casein hydrolysate formula was suspected and the infant was transferred to soy formula. Eosinophil counts decreased and transaminase levels were normalized on day 19. A cow's milk protein-specific lymphocyte proliferation test was positive for alpha-casein, beta-lactoglobulin, and bovine serum albumin, indicating sensitization of T cells to cow's milk proteins. These observations suggest that careful attention should be paid to liver dysfunction in non-immunoglobulin E-mediated cow's milk allergy, even when hypoallergenic formula is used.


Assuntos
Fórmulas Infantis , Hepatopatias/etiologia , Hipersensibilidade a Leite/complicações , Caseínas/efeitos adversos , Eosinofilia/etiologia , Humanos , Imunoglobulina E/sangue , Recém-Nascido , Masculino
13.
Am J Physiol Gastrointest Liver Physiol ; 294(1): G199-207, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17962357

RESUMO

It has been recently demonstrated that NKG2D is an activating costimulatory receptor on natural killer (NK) cells, natural killer T (NKT) cells, activated CD8(+) T cells, and gammadelta T cells, which respond to cellular stress, such as inflammation, transformation, and infection. Here we show that intestinal inflammation in colitic SCID mice induced by adoptive transfer of CD4(+)CD45RB(high) T cells is characterized by significant increase of CD4(+)NKG2D(+) T cells and constitutive expression of NKG2D ligands, such as H60, Mult-1, and Rae-1, by lamina propria CD11c(+) dendritic cells. Furthermore, treatment with nondepleting and neutralizing anti-NKG2D MAb after transfer of CD4(+)CD45RB(high) T cells into SCID mice significantly suppressed wasting disease with colitis, abrogated leukocyte infiltration, and reduced production of IFN-gamma by lamina propria CD4(+) T cells. These findings demonstrate that NKG2D signaling pathway is critically involved in CD4(+) T cell-mediated disease progression and suggest a new therapeutic target for inflammatory bowel diseases.


Assuntos
Transferência Adotiva , Anti-Inflamatórios/farmacologia , Anticorpos Monoclonais/farmacologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Colite/prevenção & controle , Colo/efeitos dos fármacos , Receptores Imunológicos/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Animais , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Antígeno CD11c/metabolismo , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/transplante , Proteínas de Transporte/metabolismo , Quimiotaxia de Leucócito/efeitos dos fármacos , Colite/imunologia , Colite/patologia , Colo/imunologia , Colo/patologia , Células Dendríticas/imunologia , Modelos Animais de Doenças , Feminino , Antígenos de Histocompatibilidade Classe I/metabolismo , Interferon gama/metabolismo , Antígenos Comuns de Leucócito/metabolismo , Ligantes , Proteínas de Membrana , Camundongos , Camundongos Endogâmicos BALB C , Camundongos SCID , Antígenos de Histocompatibilidade Menor/metabolismo , Subfamília K de Receptores Semelhantes a Lectina de Células NK , Receptores Imunológicos/imunologia , Receptores Imunológicos/metabolismo , Receptores de Células Matadoras Naturais
14.
Int J Hematol ; 84(2): 158-65, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16926139

RESUMO

The safety and efficacy of Kogenate, a recombinant factor VIII (rFVIII) preparation for the treatment of bleeding episodes, were studied in a 123-patient meta-analysis population of previously treated patients (PTPs), including 15 enrolled in the registration Phase III trial (PTP-I group), 93 from the post-marketing special investigation (PTP-II group), and 15 from short-term special investigations in surgery or tooth extraction (SI group). These patients (82 severe, 31 moderate, 9 mild, and 1 unknown), aged 11 months to 72 years, were enrolled in 28 centers in Japan. Blood samples taken at the baseline and at 3, 6, 9, 12, 18, and 24 months after the introduction of Kogenate were evaluated for FVIII inhibitor antibodies, antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Mean exposure to Kogenate was 1103 days in PTP-I, 86 days in PTP-II, 27 days in patients in surgery, and 2 days in patients with tooth extraction. Assessment of FVIII inhibitor activity was conducted in 115 of the 123 patients by means of the Bethesda assay. Twelve patients were found to have a low titer of FVIII inhibitor (0.5-3.0 BU/mL) prior to any administration of Kogenate, and 103 were inhibitor-negative at the baseline. Among this latter group, 3 patients (2.9%) tested inhibitor-positive, with titers ranging from 1.2 to 2.1 BU/mL, with 4 patients below 1.0 BU/mL. One patient in the 11 PTPs investigated (PTP-I) developed antibodies against baby hamster kidney protein and mouse immunoglobulin G, but these findings were transient and asymptomatic. Hemostasis was achieved (markedly effective or effective) in 3666 of the 3855 bleeding episodes (95.1%) observed in 108 patients. Only 1 infusion was necessary in 3790 (98.3%) of these episodes. These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A.


Assuntos
Contaminação de Medicamentos , Fator VIII/efeitos adversos , Hemofilia A/sangue , Hemorragia/sangue , Adolescente , Adulto , Idoso , Animais , Autoanticorpos/sangue , Autoanticorpos/imunologia , Inibidores dos Fatores de Coagulação Sanguínea/sangue , Inibidores dos Fatores de Coagulação Sanguínea/imunologia , Criança , Pré-Escolar , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Cricetinae , Cães , Fator VIII/administração & dosagem , Fator VIII/imunologia , Seguimentos , Hemofilia A/tratamento farmacológico , Hemofilia A/imunologia , Hemorragia/tratamento farmacológico , Hemorragia/imunologia , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Lactente , Pessoa de Meia-Idade , Fatores de Tempo
15.
J Thromb Haemost ; 4(6): 1354-60, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16706982

RESUMO

Factor (F)V is converted into its active form, FVa, by limited proteolysis. Thrombin-catalyzed activation of FV is essential for its full cofactor activation. Previously, we reported that thrombin was bound to the C2 domain in the light chain of FVIII. As FV has a similar domain structure to FVIII, we focused on the FV C2 domain as a possible binding region for thrombin. Kinetic parameters, measured by surface plasmon resonance, revealed that the K(d) values of anhydro-thrombin for FV, FVa, and the FV C2 domain were 66, 240, and 670 nmol L(-1), respectively. FV activation was increased by approximately 9-fold by the addition of thrombin. In the presence of the FV C2 domain, this increase of the FV activation was inhibited. However, FV activation was not inhibited by the addition of the FVIII C2 domain. FV was cleaved into a 105-kDa heavy chain and a 71/74-kDa light chain by thrombin-catalyzed proteolysis at Arg709, Arg1018 and Arg1545. In the presence of the FV C2 domain, the cleavage was inhibited at all sites. Proteolysis was not affected by the addition of the FVIII C2 domain. These results indicated that the FV C2 domain contains a major binding site for thrombin and that this domain is necessary for the proteolysis at all cleavage sites. Furthermore, the present results also suggested that thrombin has an independent binding site for FV different from that for FVIII.


Assuntos
Fator VIII/metabolismo , Fator V/química , Fator V/metabolismo , Fator Va/metabolismo , Trombina/metabolismo , Ligação Competitiva , Fator VIII/química , Fator Va/química , Humanos , Cinética , Ligação Proteica , Estrutura Terciária de Proteína , Ressonância de Plasmônio de Superfície
17.
J Thromb Haemost ; 4(2): 377-84, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16420569

RESUMO

BACKGROUND: Precise assessment of clotting function is essential for monitoring of hemostatic treatment for hemophilias A and B. MATERIALS AND METHODS: Clot waveform analysis and thrombin generation assays were performed on factor (F) VIII- and FIX-deficient plasmas, which had been reconstituted with known amounts of recombinant FVIII (rFVIII) and affinity-purified FIX respectively. Clot waveforms were assessed qualitatively and quantitatively by measuring the parameters clotting time, maximum coagulation velocity (Min1), and maximum coagulation acceleration (Min2). The thrombin generation assay was also assessed qualitatively and measurements made of time to peak and peak height. RESULTS: Overall results obtained with both assays showed good correlation for both clotting factors confirming that the changes in clotting waveform reflected changes in thrombin generation. Both assays demonstrated a predictable dose response to the addition of FVIII or IX. However, clot waveform analysis was more sensitive than the thrombin generation assay, particularly in detecting very low levels (0-0.1 IU dL(-1)) of both factors. CONCLUSIONS: These data suggest that the application of clot waveform analysis to the routine management of the hemophiliacs could increase our understanding of the clinical significance of low levels of FVIII and FIX that cannot be measured by assays in current use. This may be particularly useful in the management of hemophiliacs with inhibitors or undergoing gene therapy.


Assuntos
Testes de Coagulação Sanguínea/métodos , Fator IX/análise , Fator VIII/análise , Hemofilia A/sangue , Hemofilia B/sangue , Biometria , Testes de Coagulação Sanguínea/estatística & dados numéricos , Fator IX/administração & dosagem , Fator VIII/administração & dosagem , Hemofilia A/tratamento farmacológico , Hemofilia B/tratamento farmacológico , Humanos , Técnicas In Vitro , Masculino , Tempo de Tromboplastina Parcial/métodos , Tempo de Tromboplastina Parcial/estatística & dados numéricos , Proteínas Recombinantes/administração & dosagem , Sensibilidade e Especificidade , Tempo de Trombina/métodos , Tempo de Trombina/estatística & dados numéricos
18.
Clin Nephrol ; 64(5): 329-36, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16312259

RESUMO

AIM: Thin basement membrane disease (TBMD) is characterized histologically by diffuse thinning of glomerular basement membrane (GBM). Although recent genetic analysis has shown that TBMD might be included within type IV collagen disorders, conventional immunohistochemical studies demonstrated normal labeling of type IV collagen alpha chains in the GBM. We have, however, successfully used confocal laser scanning microscopy to demonstrate a significantly reduced signal of type IV collagen alpha5 chain (alpha5(IV)) along capillary walls in TBMD. In order to further understand the association of type IV collagen with TBMD, we used immunoelectron microscopy to examine renal biopsies from 6 children with TBMD and six control children with minimal change nephrotic syndrome. METHODS: Ultrathin sections of LR gold resin were incubated with a rat monoclonal antibody against human alpha1(IV), alpha2(IV), alpha3(IV), alpha4(IV) alpha5(IV) or alpha6(IV) followed by colloidal gold conjugated goat anti-rat IgG. After taking electron micrographs, the labeling was quantitatively evaluated in the area occupied by the segments of basement membrane. The basement membrane was divided into three equal segments viz. subepithelial side, central portion and subendothelial side. RESULTS: In control subjects, the number of gold particles for alpha1(IV) or alpha2(IV) was significantly greater in the subendothelial side and central portion than in the subepithelial side of the GBM, whilst alpha3(IV), alpha4(IV) or alpha5(IV) labeling was significantly more prominent in the central portion compared to the subepithelial and subendothelial side of the GBM. TBMD samples showed a similar distribution pattern except that the subepithelial side and central portion of the GBM had a significantly reduced amount of alpha5(IV) antigen compared to control subjects. CONCLUSION: This is the first report demonstrating a diminished labeling intensity of alpha5(IV) in the central portion and subepithelial side of the GBM in renal biopsy specimens from patients with TBMD. These findings suggest that an abnormality of alpha5(IV) might possibly be associated with the pathogenesis of TBMD.


Assuntos
Colágeno Tipo IV/análise , Membrana Basal Glomerular/química , Nefropatias/patologia , Adolescente , Criança , Feminino , Humanos , Nefropatias/genética , Masculino , Microscopia Imunoeletrônica , Linhagem
19.
Oral Dis ; 11(4): 243-8, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15984956

RESUMO

OBJECTIVES: To develop plans for the haemostatic management of intraoral bleeding in patients with von Willebrand disease (VWD). SUBJECTS AND METHODS: Thirty-seven episodes of haemostatic management of intraoral bleeding in 19 VWD patients were analysed retrospectively based on the medical records. RESULTS AND CONCLUSIONS: When performing tooth extractions in patients with type 1 or 2A VWD [responsive to 1-deamino-8-D-arginine-vasopressin (DDAVP)], 0.35-0.4 microg kg(-1) of DDAVP should be administered intravenously at three times. In patients with type 2A VWD (unresponsive to DDAVP) or patients with type 2B or 2N VWD, 50-90 U [as ristocetin cofactor (VWF:RCof)] kg(-1) of a factor VIII concentrate containing von Willebrand factor (FVIII/VWF concentrate) should be administered twice in routine extractions, and four to six times in surgical extractions. Gingival bleeding related to primary teeth can be mostly managed by pressure haemostasis alone. However, when treating gingival bleeding caused by marginal periodontitis, it is often necessary to administer 0.4 microg kg(-1) of DDAVP or 40-70 U (as VWF:RCof) kg(-1) of a FVIII/VWF concentrate. As local haemostasis is difficult to achieve in bleeding from the tongue or labial or mandibular haematoma, it is necessary to administer 0.4 microg kg(-1) of DDAVP or 60-80 U (as VWF:RCof) kg(-1) of a FVIII/VWF concentrate. In addition, oral administration of 20 mg kg(-1) day(-1) of tranexamic acid should be combined with the regimens described above.


Assuntos
Assistência Odontológica para Doentes Crônicos , Hemostáticos/uso terapêutico , Hemorragia Bucal/prevenção & controle , Hemorragia Pós-Operatória/prevenção & controle , Doenças de von Willebrand , Adolescente , Adulto , Criança , Desamino Arginina Vasopressina/uso terapêutico , Fator VIII/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Hemorragia Pós-Operatória/etiologia , Pressão , Estudos Retrospectivos , Extração Dentária/efeitos adversos , Ácido Tranexâmico/uso terapêutico , Doenças de von Willebrand/complicações , Fator de von Willebrand/uso terapêutico
20.
Transplant Proc ; 37(2): 1131-3, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15848646

RESUMO

Metabolic liver disease can be cured by orthotopic liver transplantation. Some successful cases of whole or partial liver transplantation have been reported. Because liver function in these recipients is normal save for the production of the responsive metabolic factor, auxiliary partial orthotopic liver transplantation (APOLT) may produce a benefit. However, no experimental model of APOLT for metabolic liver diseases has been reported. We established a canine APOLT model to evaluate the clinical feasibility and efficacy of APOLT to cure hemophilia. The donor normal beagle dog was used to establish an APOLT model. A left lobe partial liver graft taken from the donor was orthotopically transplanted to the recipient after resection of the native left lobe preserving the native right lobe. Recipients showed no atrophy and comparable blood flow in both the graft and the native liver at the time of exploration after APOLT. Thus, APOLT was performed from a normal donor to a recipient with hemophilia A. In this recipient, blood factor VIII activity markedly increased after APOLT and was maintained for 7 weeks. No episode of bleeding was seen during the observation. In conclusion, a canine APOLT model was successfully established as evidenced by sustained production of factor VIII in a hemophilia recipient. These findings suggest the clinical feasibility and efficacy of APOLT for metabolic liver diseases.


Assuntos
Fator VIII/análise , Hemofilia A/cirurgia , Transplante de Fígado/métodos , Animais , Bilirrubina/sangue , Biomarcadores/sangue , Modelos Animais de Doenças , Cães , Estudos de Viabilidade , Sobrevivência de Enxerto , Transplante de Fígado/fisiologia , Masculino , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...